Читать книгу The SAGE Encyclopedia of Stem Cell Research - Группа авторов - Страница 245

Gene expression profiling has suggested that triple-negative breast cancer might be preferentially sensitive to inhibition of the proto-oncogene Src. Dasatinib, a potent orally available inhibitor of Src-family kinase, is being studied in the setting of advanced triple-negative breast cancer patients.